Enveda Raises $311M to Push Nature-Derived AI Drugs

Much of the attention in AI drug discovery goes to models that design molecules from scratch. Enveda starts somewhere else: with the chemistry that plants and microbes have already produced.

Investors have now backed that approach with more money. The biotech startup has raised a $311 million Series E at a $2 billion valuation. Catalio Capital Management led the round, and Iconiq was among the other participants. The new valuation is double the one Enveda reached 12 months ago.

Nature as the starting library

Conventional drug discovery often means building a compound in the lab and then testing whether it does anything useful. Enveda's premise is that many powerful medicines may already exist in plants and microbes, waiting to be found and put to use.

The difficulty has always been speed. The natural world holds an enormous range of chemistry, and working out which molecules matter, and what they do, is slow. Enveda was built to speed that up. Viswa Colluru founded the company in 2019 to accelerate the discovery of these drugs using AI alongside other techniques.

Colluru's background helps explain the idea. He was an early employee at Recursion Pharmaceuticals, another company that has built its identity around bringing computation into drug discovery.

What Enveda is testing in patients

A round of this size is rarely about the discovery platform alone. Investors are paying for what comes out of it, and Enveda now has candidates in the clinic. The company is testing several drugs in patients.

Two stand out. One targets severe skin conditions. The other addresses a problem that has grown with the popularity of GLP-1 medicines: it is designed to help people keep weight off after they stop taking them.

That second programme shows how the company is positioning itself. It does not compete head-on with existing weight-loss drugs. It focuses on what happens afterwards, a gap that matters more as more patients start and later stop these treatments.

No FDA-approved AI drug yet

For all the capital moving into the field, one fact sets the limits of the discussion. AI has not yet produced a drug approved by the FDA.

Enveda is part of a wave of companies trying to change that by taking AI-discovered candidates into human clinical trials. That is where the real test begins. Algorithms can narrow the search and shorten the early stages of discovery. But a candidate still has to show that it is safe and effective in people, and that process does not run at software speed.

The valuation is therefore best read as a vote of confidence in a pipeline, not a verdict on it. Doubling in a year shows that investors believe the approach can deliver clinical results. Whether it does will be decided by trial data, not by funding announcements.

Why it matters: specialised AI in the life sciences

For readers who follow AI mainly through chatbots and coding tools, Enveda is a reminder that some of the most consequential uses of the technology sit in narrow, demanding domains. The key question here is not how general a model is. It is whether the model helps find a molecule that treats a disease.

The deal also fits a broader shift of AI towards biology, a trend visible in efforts such as Anthropic's biology lab, which recently reported finding a CRISPR-like enzyme. And it shows that multibillion-dollar valuations are not limited to consumer-facing AI companies such as voice AI firm ElevenLabs. Biotech startups with drugs in trials are attracting serious capital too.

There is a difference, though. A software company can show progress through usage and revenue. A drug discovery company has to show it through patients. Enveda's skin and weight-maintenance programmes are now the measure that matters. The new funding gives the company room to take more nature-derived candidates into trials, and the clinical results will show whether AI can turn the chemistry of the natural world into approved medicines.